Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ankyrin repeat domain-containing protein 50 (ANKRD50) is characterized by its ankyrin repeat domains, which fold into stable, L-shaped structures that facilitate protein-protein interactions[2]. ANKRD50 participates in the trafficking and recycling of proteins between endosomes and the plasma membrane, being critical for the regulation of SNX27-retromer-dependent cargo such as the glucose transporter GLUT1[3]. Defects or mutations in ANKRD50 have been associated with autosomal recessive intellectual disability and immunodeficiency syndromes[3]. Based on current data, it is not classified as a receptor, enzyme, ion channel, or direct pharmacological target, but rather as a scaffold/adaptor protein within the ankyrin repeat family[1][2][3][4].
null
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ankyrin repeat domain-containing protein 50 (ANKRD50).